| 000 | 04297naa a22005897i 4500 | ||
|---|---|---|---|
| 001 | UMUN-OA-20261005-MLS-024 | ||
| 003 | local | ||
| 005 | 20261005174903.0 | ||
| 006 | m o d | ||
| 007 | cr|||||||||||| | ||
| 008 | 261005s2017 xx o u000 0 eng d | ||
| 024 | 7 |
_a10.1007/s12325-017-0612-x _2doi |
|
| 035 | _a(local)EuropePMC:PMC5656728 | ||
| 040 |
_alocal _beng _clocal |
||
| 041 | 0 | _aeng | |
| 100 | 0 |
_aGilles Salles _eauthor. |
|
| 245 | 1 | 0 |
_aRituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. / _cGilles Salles; Martin Barrett; Robin Foà [and others]. |
| 264 | 1 |
_a[Place of publication not identified] : _b[publisher not identified], _c2017. |
|
| 300 | _a1 online resource (1 article). | ||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_acomputer _bc _2rdamedia |
||
| 338 |
_aonline resource _bcr _2rdacarrier |
||
| 500 | _aPublication type: Review article. | ||
| 500 | _aLinked open-access copy: published version. | ||
| 506 | 0 |
_aOpen access; no subscription required for the linked open-access version. _fUnrestricted online access _2star |
|
| 520 | 3 | _aRituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established efficacy, and a favorable and well-defined safety profile in patients with various CD20-expressing lymphoid malignancies, including indolent and aggressive forms of B-cell non-Hodgkin lymphoma. Since its first approval 20 years ago, intravenously administered rituximab has revolutionized the treatment of B-cell malignancies and has become a standard component of care for follicular lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia, and mantle cell lymphoma. For all of these diseases, clinical trials have demonstrated that rituximab not only prolongs the time to disease progression but also extends overall survival. Efficacy benefits have also been shown in patients with marginal zone lymphoma and in more aggressive diseases such as Burkitt lymphoma. Although the proven clinical efficacy and success of rituximab has led to the development of other anti-CD20 monoclonal antibodies in recent years (e.g., obinutuzumab, ofatumumab, veltuzumab, and ocrelizumab), rituximab is likely to maintain a position within the therapeutic armamentarium because it is well established with a long history of successful clinical use. Furthermore, a subcutaneous formulation of the drug has been approved both in the EU and in the USA for the treatment of B-cell malignancies. Using the wealth of data published on rituximab during the last two decades, we review the preclinical development of rituximab and the clinical experience gained in the treatment of hematologic B-cell malignancies, with a focus on the well-established intravenous route of administration. This article is a companion paper to A. Davies, et al., which is also published in this issue. Funding F. Hoffmann-La Roche Ltd., Basel, Switzerland. | |
| 540 |
_aCreative Commons Attribution-NonCommercial. See the linked licence for the applicable terms. _uhttps://creativecommons.org/licenses/by-nc/4.0/ |
||
| 546 | _aIn English. | ||
| 588 | 0 | _aDescription generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source. | |
| 590 | _aCourse allocation: B. Sc. Medical Laboratory Science. | ||
| 650 | 4 | _aSafety | |
| 650 | 4 | _aMonoclonal antibody | |
| 650 | 4 | _aCD20 | |
| 650 | 4 | _aTreatment outcome | |
| 650 | 4 | _aFollicular Lymphoma | |
| 650 | 4 | _aRituximab | |
| 653 | _aB. Sc. Medical Laboratory Science | ||
| 653 | _aUMUN open access collection | ||
| 653 | _ahematology | ||
| 655 | 4 | _aReview articles. | |
| 700 | 0 |
_aMartin Barrett _eauthor. |
|
| 700 | 0 |
_aRobin Foà _eauthor. |
|
| 700 | 0 |
_aJoerg Maurer _eauthor. |
|
| 700 | 0 |
_aSusan O'Brien _eauthor. |
|
| 700 | 0 |
_aNancy Valente _eauthor. |
|
| 700 | 0 |
_aMichael Wenger _eauthor. |
|
| 700 | 0 |
_aDavid G Maloney _eauthor. |
|
| 773 | 0 |
_tAdvances in therapy _gVol. 34, no. 10, (2017), pages/article 2232-2273 _x0741-238X |
|
| 856 | 4 | 0 |
_uhttps://europepmc.org/articles/PMC5656728 _yRead open-access publication _zOpen access. _70 |
| 884 |
_aCourse selection and automated MARC21 enrichment from Europe PMC metadata. _g20261005 _khttps://europepmc.org/articles/PMC5656728 _qlocal |
||
| 942 | _n0 | ||
| 999 |
_c1166 _d1166 |
||